Australia's most trusted
source of pharma news
Posted 31 July 2025 PM
Lifting PBS restrictions that prevent single pill combinations (SPC) being used in the first line to treat hypertension would not only improve patient care but also deliver substantial cost savings to both the government and consumers.
A new Australian study, led by The George Institute for Global Health with support from Lund University, analysed 57 SPCs listed on the PBS and found the cost in nearly all cases was less, with an average saving of 30 per cent for general patients before reaching the safety net.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.